3,305 Shares in ABIOMED, Inc. (NASDAQ:ABMD) Acquired by Harvest Investment Services LLC

Harvest Investment Services LLC bought a new position in shares of ABIOMED, Inc. (NASDAQ:ABMD) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,305 shares of the medical equipment provider’s stock, valued at approximately $917,000.

Several other institutional investors also recently made changes to their positions in ABMD. Norges Bank acquired a new stake in shares of ABIOMED during the fourth quarter worth $158,786,000. Baillie Gifford & Co. raised its position in ABIOMED by 32.8% during the fourth quarter. Baillie Gifford & Co. now owns 1,068,859 shares of the medical equipment provider’s stock valued at $347,422,000 after buying an additional 264,252 shares during the period. Vanguard Group Inc raised its position in ABIOMED by 5.9% during the third quarter. Vanguard Group Inc now owns 4,647,227 shares of the medical equipment provider’s stock valued at $2,090,091,000 after buying an additional 260,829 shares during the period. Vanguard Group Inc. raised its position in ABIOMED by 5.9% during the third quarter. Vanguard Group Inc. now owns 4,647,227 shares of the medical equipment provider’s stock valued at $2,090,091,000 after buying an additional 260,829 shares during the period. Finally, Marshall Wace North America L.P. raised its position in ABIOMED by 45.1% during the third quarter. Marshall Wace North America L.P. now owns 690,160 shares of the medical equipment provider’s stock valued at $310,399,000 after buying an additional 214,655 shares during the period. 87.99% of the stock is currently owned by institutional investors.

Several research firms recently weighed in on ABMD. ValuEngine raised ABIOMED from a “hold” rating to a “buy” rating in a research report on Tuesday, February 12th. BidaskClub lowered ABIOMED from a “buy” rating to a “hold” rating in a research report on Wednesday, February 27th. Zacks Investment Research lowered ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, BTIG Research reissued a “buy” rating and set a $400.00 price target on shares of ABIOMED in a research report on Tuesday, January 22nd. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $408.67.

In other ABIOMED news, Director Martin P. Sutter sold 20,000 shares of the business’s stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $360.16, for a total value of $7,203,200.00. Following the transaction, the director now owns 195,491 shares in the company, valued at $70,408,038.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Martin P. Sutter sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $360.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director now owns 195,491 shares in the company, valued at approximately $70,376,760. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

Shares of NASDAQ ABMD opened at $261.94 on Friday. ABIOMED, Inc. has a one year low of $228.00 and a one year high of $459.75. The stock has a market capitalization of $11.73 billion, a price-to-earnings ratio of 72.76, a PEG ratio of 2.04 and a beta of 0.29.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.53. ABIOMED had a return on equity of 20.32% and a net margin of 33.66%. The firm had revenue of $207.08 million for the quarter, compared to the consensus estimate of $218.88 million. During the same quarter in the previous year, the company posted $0.80 earnings per share. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. As a group, equities research analysts forecast that ABIOMED, Inc. will post 4.78 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/10/harvest-investment-services-llc-acquires-shares-of-3305-abiomed-inc-abmd.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: Do stock splits help investors?

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.